Clinical-stage oncology company Revolution Medicines and fellow USA-based Summit Therapeutics have entered into a clinical ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Redwood City, Calif.-based Revolution Medicines is a late-stage clinical oncology company whose clinical-stage inhibitors include daraxonrasib, zoldonrasib, and elironrasib. Summit is a Miami-based ...

Revolution Medicines, Inc. (RVMD) and Summit Therapeutics, Inc. (SMMT) have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of ...

Tango Therapeutics has dosed the first subject in the Phase I/II trial assessing TNG462 in combination with Revolution ...

Tango Therapeutics shares climbed after it said the first patient has been dosed in its early stage study of a therapy for patients with a certain type of pancreatic or lung cancer. Shares recently ...

Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide ...

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated with Sarepta's therapy.

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at ...